Bryan, Garnier & Co's News

Read all the news of the independent investment banking dedicated to Growth
Share on
Filters

Voltalia: An acquisition that makes sense, despite being dilutive on margin

BUY, Fair Value EUR13 (+46%)

Published last June Tuesday 21, 2016

Roche: APHINITY – it is worth taking the residual risk

BUY, Fair Value CHF293 (+19%)

Published last June Tuesday 21, 2016

AXA: At first sight the 2020 plan looks solid

BUY-Top Picks, Fair Value EUR29 (+41%)

Published last June Tuesday 21, 2016

Dassault Systèmes: Feedback from Capital Markets Day: highlighting the value-based approach

SELL, Fair Value EUR63 vs. EUR62 (-6%)

Published last June Monday 13, 2016

Genmab: Daratumumab caught everyone's eye once again

BUY, Fair Value Under Review

Published last June Monday 13, 2016

Morphosys "Back for MORe"

FV EUR62 BUY Coverage initiated

Published last June Monday 13, 2016
Bryan, Garnier & Co annouces the successful closing of Soitec’s €75.4 million Rights Issue

Bryan, Garnier & Co annouces the successful closing of Soitec’s €75.4 million Rights Issue

Published last June Thursday 9, 2016

Groupe SEB The kitchen is now bigger and well-equipped!

Published last May Tuesday 31, 2016

A more focused Sanofi is on the way

FV EUR83 vs. EUR86 NEUTRAL

Published last May Monday 30, 2016

Albioma: Further development in Brazil, as planned by management

BUY, Fair Value EUR16 (+12%)

Published last May Monday 30, 2016

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities